A new clinical study, sponsored by Swedish health technology company Qbtech AB, is set to expand normative data for QbMobile, an investigational software application aimed at cognitive performance and activity measurement for children aged 6–11 years. The non-recruiting study, listed under ClinicalTrials.gov record NCT07330960, targets healthy volunteers and aims to refine additional baseline measures for this next-generation digital health tool.
QbMobile, a state-of-the-art digital device currently classified as investigational, continues to attract attention for its potential in setting new standards in cognitive activity monitoring. This announcement is particularly significant for clinical, regulatory, and quality management professionals active in pediatric health device innovations.
In this article:
- What changed?
- Objective of the study
- Implications for regulatory progress
- FAQ
- Conclusion
- Disclaimer
- Source and additional information
What changed?
On January 10, 2026, Qbtech AB shared its intent to begin a clinical trial designed to enhance existing normative datasets for QbMobile. While recruitment is not yet underway, this move demonstrates a steady commitment to strengthening scientific validation of the device in child cohorts. The study focuses on improving reliability of this investigational technology, supporting its broader application in pediatric health monitoring.
Objective of the study
The study aims to augment baseline data associated with QbMobile by examining health metrics in children aged 6–11 years. As an investigational device, QbMobile measures cognitive performance and physical activity through user-friendly digital platforms. By involving a healthy volunteer demographic, the trial seeks to validate key metrics that can eventually be translated into clinical applications or neurobehavioral assessments.
Implications for regulatory progress
This trial represents an important stage in the lifecycle of any regulated medical device: alignment with statutory definitions of safety, clinical performance, and intended purpose under global and local regulations, such as the EU Medical Devices Regulation (MDR) or US FDA premarket processes. Augmenting normative datasets plays a critical role in ensuring the device’s efficacy and reliability before broader market authorization or physician use cases.
Integrating pediatric-specific data offers regulators clear evidence of population-specific efficacy, particularly within such a sensitive demographic. Stakeholders in medical device regulation, from clinical professionals to quality assurance teams in the industry, will find these results inherently valuable when taking this product pathway into account.
FAQ
1. What is QbMobile?
QbMobile is an investigational software application that focuses on cognitive performance and activity measurement in pediatric and potentially other user demographics.
2. What population does this study focus on?
The study focuses on healthy children aged 6–11 years to enhance available normative data.
3. Is recruitment currently open for this trial?
No, the ClinicalTrials.gov record states the trial is not yet recruiting.
4. Why is this study important?
It supports future applications of QbMobile by refining normative benchmarks tied to safe and effective use, providing crucial evidence to regulatory authorities.
Conclusion
This upcoming study is a vital step forward in strengthening and expanding QbMobile’s usability within pediatric healthcare. By targeting healthy children, Qbtech AB ensures developmental benchmarks are captured accurately and comprehensively for regulatory and clinical validations.
Disclaimer
Content in this article is for informational and educational use only and does not constitute legal, regulatory, or clinical advice. Always consult appropriate specialists when interpreting or applying any related information.
Source and additional information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07330960?term=medical+device